吉非替尼联合重组人血管内皮抑制素治疗EGFR突变非小细胞肺癌的临床效果观察  

Clinical Efficacy of Gefitinib Combined with Recombinant Human Endostatin in Treatment of NSCLC Patients with EGFR Gene Mutation

作　　者：刘世光 田伶伶 史冬梅 王聪[2] 刘聪[3] LIU Shi-guang;TIAN Ling-ling;SHI Dong-mei;WANG Cong;LIU Cong(Department of Oncology,the Central Hospital of Liaoyang City,Liaoyang,Liaoning 111000,China;Department of Mammary Gland Surgery,the Cancer Hospital of Liaoning Province,Shenyang 110042,China;Department of Oncology,the Central Hospital of Tieling City,Tieling,Liaoning 112001,China)

机构地区：[1]辽阳市中心医院乳腺外科,辽宁辽阳111000 [2]辽宁省肿瘤医院乳腺外科,沈阳110042 [3]铁岭市中心医院肿瘤内科,辽宁铁岭112001

出　　处：《解放军医药杂志》2022年第3期6-9,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：辽宁省自然科学基金资助项目(2015-ZD-0713)。

摘　　要：目的观察吉非替尼联合重组人血管内皮抑制素治疗表皮生长因子受体(EGFR)突变非小细胞肺癌(NSCLC)的临床效果。方法选取2018年5月—2020年11月本院收治的109例EGFR突变NSCLC,根据治疗方法的不同分为研究组55例(予吉非替尼联合重组人血管内皮抑制素治疗)和对照组54例(仅予吉非替尼治疗),21 d为1个治疗周期,共治疗4个周期。比较2组临床疗效,治疗前后血清肿瘤标志物[癌胚抗原(CEA)、血管内皮生长因子(VEGF)、细胞角蛋白19片段抗原(CYFRA21-1)]水平及生活质量和治疗期间不良反应发生情况。结果研究组总有效率及疾病控制率均高于对照组(P<0.05)。治疗后,2组CEA、VEGF、CYFRA21-1水平均下降,且研究组低于对照组(P<0.05,P<0.01)。治疗2、4个周期后,2组生活质量调查表肺癌13评分均升高,且研究组高于对照组(P<0.05,P<0.01)。2组治疗期间不良反应比较差异无统计学意义(P>0.05)。结论吉非替尼联合重组人血管内皮抑制素治疗EGFR突变NSCLC,能有效提高患者疗效,降低血清肿瘤标志物水平,改善生活质量,且安全性较好。Objective To observe clinical efficacy of Gefitinib combined with recombinant human endostatin in treatment of non-small cell lung cancer(NSCLC)patients with epidermal growth factor receptor(EGFR)gene mutation.Methods A total of 109 NSCLC patients with EGFR gene mutation admitted between May 2018 and November 2020 were selected,and the patients were divided into research group(treated with Gefitinib combined with recombinant human endostatin,n=55)and control group(treated with Gefitinib only,n=54)according to different therapeutic methods.One treatment cycle was 21 d,and a total of 4 cycles were given.Clinical efficacy,serum levels of tumor markers[carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF),cytokeratin 19 fragment antigen(CYFRA21-1)]before and after treatment,the quality of life incidence rate of adverse reactions during treatment were compared between the groups.Results The total effective rate and disease control rate in research group were significantly higher than those in control group(P<0.05).After treatment,levels of CEA,VEGF and CYFRA21-1 were significantly lower than those before treatment in two groups,and the levels in research group were significantly lower than those in control group(P<0.05,P<0.01).After treatment for 2 and 4 cycles,the scores of the quality of life questionnaire-lung cancer 13 were significantly larger than those before treatment in two groups,and the score in research group was significantly larger than that in control group(P<0.05,P<0.01).There was no significant difference in incidence rate of adverse reactions during treatment between two groups(P>0.05).Conclusion Gefitinib combined with recombinant human endostatin in treatment of NSCLC patients with EGFR gene mutation may effectively improve clinical efficacy,reduce serum levels of tumor markers and improve the quality of life with good safety.

关 键 词：癌 非小细胞肺 受体 表皮生长因子 吉非替尼 重组人血管内皮抑制素 癌胚抗原 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]